Abstract Glucagon-like peptide-1 (GLP-1) agonists are very popular and useful medications
for the treatment of type 2 diabetes mellitus and obesity. Potent gastric emptying delay is …

We read with great interest the review by Milder et al. on the implications of glucagon-like
peptide-1 (GLP-1) receptor agonists on peri-operative care and welcome recommendations …

Glucagon‑like peptide‑1 (GLP‑1) agonists are here to stay to pharmacologically mitigate the
increasing prevalence of diabetes mellitus and morbid obesity.[1] Just like the increased …

Importance Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is rapidly increasing in
the US, driven by its expanded approval for weight management in addition to …

Recently, there has been increased interest in the relationship between glucagon-like
peptide 1 (GLP-1) receptor agonists, delayed gastric emptying, and subsequent risk of …

We thank Drs Hurley and Kearsley for their comments [1] on our review on the implications
of glucagon-like peptide-1 (GLP-1) receptor agonists on peri-operative care [2], and for …

We would like to draw attention to a concerning issue regarding the use of glucagon-like
peptide 1 (GLP-1) agonists, commonly prescribed for diabetes management and weight …

Prescriptions and use of glucagon-like peptide-1 (GLP-1) receptor agonists are increasing
dramatically, as indications are expanding from the treatment of diabetes mellitus to weight …

New classes of antihyperglycemic agents con-tinue to be introduced for the management of
diabetes mellitus (DM). 1 Endogenous glucagon-like peptide-1 (GLP-1) is an incretin …

Abstract Glucagon-like peptide 1 (GLP-1) receptor agonists have surged in popularity for the
treatment of both diabetes mellitus and obesity. While GLP-1 reduces proximal …